Skip to main content

Table 4 HI seroconversion rates and seroconversion factors in response to vaccination

From: Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older

Group Day N A/Brisbane A/Uruguay B/Brisbane
    % seroconversion rate (95% CI)a
TIV/AS03 (≥65) 21 62 58 (45–71) 84 (72–92) 71 (58–82)
42 61 54 (41–67) 79 (66–88) 62 (49–74)
180 62 26 (15–39) 58 (45–71) 35 (24–49)
TIV(≥65) 21 66 48 (36–61) 76 (64–86) 58 (45–70)
42 65 38 (27–51) 68 (55–79) 54 (41–66)
180 66 24 (14–36) 42 (30–55) 33 (22–46)
TIV(18-40) 21 43 67 (51–81) 77 (61–88) 67 (51–81)
42 44 66 (50–80) 68 (52–81) 57 (41–72)
  180 43 53 (38–69) 46 (31–62) 46 (31–62)
    Seroconversion factor (95% CI) a
TIV/AS03 (≥65) 21 62 6.4 (4.5–9.0) 15 (11–22) 7.6 (5.6–10)
42 61 5.1 (3.7–7.0) 12 (8.5–17) 5.4 (4.0–7.2)
180 62 2.3 (1.8–3.0) 5.5 (4.1–7.3) 2.8 (2.2–3.4)
TIV(≥65) 21 66 4.7 (3.4–6.6) 9.4 (6.6–13) 5.2 (3.8–7.1)
42 65 3.9 (2.8–5.4) 6.4 (4.7–8.6) 4.1 (3.1–5.4)
180 66 2.2 (1.7–3.0) 3.4 (2.5–4.6) 2.5 (1.9–3.1)
TIV(18-40) 21 43 11 (6.3–18) 11 (7.2–18) 7.4 (4.7–12)
42 44 8.9 (5.3–15) 7.9 (5.3–12) 5.8 (3.7–8.9)
  180 43 4.6 (2.9–7.2) 4.5 (3.0–6.9) 4.0 (2.8–5.8)
  1. aValues reported at two significant figures.
  2. TIV, trivalent influenza vaccine; TIV/AS03, AS03-adjuvanted trivalent influenza vaccine.